Hakutulokset - Richárd Márkus

  • Näytetään 1 - 7 yhteensä 7 tuloksesta
Tarkenna hakua
  1. 1
    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects

    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects Tekijä Vladimir Hanes, Vincent Chow, Nan Zhang, Richárd Márkus

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab Tekijä Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community Tekijä Richárd Márkus, Jennifer Liu, Monica Ramchandani, Diana Landa, Teresa L. Born, Primal Kaur

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Estimation of Cachexia among Cancer Patients Based on Four Definitions

    Estimation of Cachexia among Cancer Patients Based on Four Definitions Tekijä Kathleen M. Fox, John M. Brooks, Shravanthi R. Gandra, Richárd Márkus, Chiun‐Fang Chiou

    Julkaistu 2009
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial Tekijä Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richárd Márkus, Stephen J. McCormack, John Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, Pål Johansen, Thomas M. Kündig

    Julkaistu 2008
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Tekijä Ronald L. Gibson, George Retsch‐Bogart, Christopher M. Oermann, Carlos Milla, Joseph M. Pilewski, Cori Daines, Richard C. Ahrens, Kevin León, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richárd Márkus, Jane L. Burns

    Julkaistu 2006
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives Tekijä Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richárd Márkus, Ursula A. Matulonis, Denise K. Reinke, Edward C. Li, Jessica K. DeMartino, Jonathan K. Larsen, James M. Hoffman

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: